Brian Atwood, Director at Immune Design, holds 19.73M shares in CERo Therapeutics Holdings (Ticker: CERO), holds 49.65K shares in Atreca (Ticker: BCEL), holds 160.19K shares in Clovis Oncology (Ticker: CLVSQ).
Brian Atwood latest transaction was an Uninformative Buy of $1.94M.
What was Brian Atwood's most profitable transaction?
Brian Atwood’s most profitable transaction was an Informative Buy of IMDZ stock on July 31, 2014. The return on the trade was 61.30%.
What is Brian Atwood's role in Immune Design?
Brian Atwood's role in Immune Design is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.